Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986449 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation: BMS-986449 monotherapy | EXPERIMENTAL | - |
| Dose Escalation: BMS-986449 + nivolumab | EXPERIMENTAL | - |
| Dose Escalation: BMS-986449 monotherapy pharmacodynamic (PD) cohorts | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986449 | DRUG | Specified dose on specified days |
| Nivolumab | DRUG | Specified dose on specified days |
Inclusion Criteria: * All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy (measurable by Response Evaluation Criteria in Solid Tumors \[RECIST\] v1.1), and have received, be refractory to, ineligible for, or intolerant of exist...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-986449 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, and it is being evaluated both alone and in combination with nivolumab in patients with advanced solid tumors.
BMS-986449 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company is conducting a Phase 1 clinical trial of this investigational small molecule in advanced solid tumors.
BMS-986449 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is active but not recruiting participants, and it is studying the drug with and without nivolumab in advanced solid tumors.
BMS-986449 is being studied in one active Phase 1 clinical trial, identified as NCT05888831. This trial is evaluating BMS-986449 with and without nivolumab in participants with advanced solid tumors, with a planned enrollment of 100 participants across the United States, Belgium, France, Italy, Netherlands, and Spain.
The specific molecular target of BMS-986449 has not been disclosed in the available information. It is a small molecule modality, and its mechanism of action is being investigated in the context of advanced solid tumors, both as a monotherapy and in combination with nivolumab.